Compare Citius Pharmaceuticals Inc (CTXR) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Las Vegas Sands Corp. — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Las Vegas Sands Corp. trades at $36.3 (market cap $23.38B). The key difference: Las Vegas Sands Corp. is far larger — about 1716.6× Citius Pharmaceuticals Inc's market cap, and Las Vegas Sands Corp. pays a 3.32% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Las Vegas Sands Corp. for 72 Days on average.
| CTXR | LVS | |
|---|---|---|
Market Cap | $13.62M | $23.38B |
Volume | 132,438 | 6,994,661 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $69.49 |
52-Week Low | $0.48 | $35.81 |
Typical Hold Time | 16 Days | 72 Days |
Enterprise Value | $3.79M | $35.27B |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
LVS trades at $35.81, down 1.38% today, with a bearish technical signal despite bullish oscillators. The company shows strong fundamentals with 2025 revenue of $13.02B and net income of $1.63B, supported by consistent earnings beats in recent quarters. Analyst consensus remains strongly bullish with 59% buy ratings and a $59.78 price target, representing 67% upside potential from current levels.
LVS presents compelling value with attractive valuation multiples (P/E 13.99, EV/EBITDA 7.64) and robust profitability (ROE 134.29%). Key risks include high debt levels (debt-to-asset ratio 73.15%) and sensitivity to Macao gaming regulations. The stock's current discount to analyst targets offers significant upside if operational momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
